It’s hard to hit a target that is standing still, and hitting a moving target is even harder. Drug targets are not static—they are constantly in motion, like origami folding. Genesis has developed a technology platform that combines molecular dynamic simulation with both generative and predictive AI models to design drugs against these moving targets. Genesis has multiple preclinical programs and also has partnered discovery programs with both Eli Lilly and Genentech. Menlo Ventures invested in their Series A in 2020.
Greg is a partner at Menlo Ventures, where he invests in teams trying to solve major problems in life science and healthcare, with a special interest in novel therapeutic platforms, digital health, and transformative technologies. Since joining in 2017, Greg has led Menlo investments including Cartwheel, Clear Labs, Curie, Delfi,…
